Neurology
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial.
Pregabalin, an alpha2-delta ligand with analgesic, anxiolytic, and anticonvulsant activity, has been evaluated for treatment of neuropathic pain. The authors assessed the efficacy and tolerability of pregabalin (75, 300, 600 mg/day) vs placebo in patients with diabetic peripheral neuropathy (DPN). ⋯ In patients with diabetic peripheral neuropathy, pregabalin demonstrated early and sustained improvement in pain and a beneficial effect on sleep, which were confirmed by positive patient global impression. Pregabalin was well tolerated at all doses.
-
Multicenter Study
Intracranial arterial dolichoectasia is associated with enlarged descending thoracic aorta.
Intracranial arterial dolichoectasia (IADE) is defined as an increase in length and diameter of the intracranial arteries and is present in 12% of stroke patients. The pathophysiology is unknown; some data suggest that IADE is not merely a complication of atherosclerosis, but a distinct arteriopathy characterized by loss of elastic tissue in the media. ⋯ Patients with intracranial arterial dolichoectasia (IADE) have larger descending thoracic aorta diameters than non-IADE patients, suggesting that the underlying process causing IADE also affects the descending thoracic aorta.
-
Interferon beta (IFNbeta) is the first-line treatment for patients diagnosed with multiple sclerosis (MS). In patients with MS who experience breakthrough disease while receiving treatment with IFNbeta, it is common clinical practice to administer additional therapeutic agents. ⋯ Agents used concomitantly have the potential to exert synergistic effects and slow the progression of disease in patients who experience breakthrough disease. Concomitant therapies that have been reported in patients with MS are reviewed here.
-
To evaluate whether baseline levels of plasma and CSF HIV RNA, tumor necrosis factor alpha (TNFalpha), monocyte chemoattractant protein-1 (MCP-1), matrix metalloproteinase-2 (MMP-2), or macrophage colony stimulating factor (M-CSF) are predictors of incident HIV-associated dementia (HIVD) in a cohort with advanced HIV infection. ⋯ The lack of association between baseline plasma and CSF HIV RNA levels and incident dementia suggests highly active antiretroviral therapy may be affecting CNS viral dynamics, leading to lower HIV RNA levels, and therefore weakening the utility of baseline HIV RNA levels as predictors of HIV-associated dementia.